Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Enrichment of extracellular vesicles with lipid nanoprobe functionalized nanostructured silica.

Wan Y, Maurer M, He HZ, Xia YQ, Hao SJ, Zhang WL, Yee NS, Zheng SY.

Lab Chip. 2019 Jul 9;19(14):2346-2355. doi: 10.1039/c8lc01359d.

PMID:
31232418
2.

Comparing preoperative dating and postoperative dating for second-trimester surgical abortions.

Mokkarala S, Creinin MD, Wilson MD, Yee NS, Hou MY.

Contraception. 2019 Jun 19. pii: S0010-7824(19)30208-2. doi: 10.1016/j.contraception.2019.06.008. [Epub ahead of print]

PMID:
31226319
3.

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.

Merle P, Blanc JF, Phelip JM, Pelletier G, Bronowicki JP, Touchefeu Y, Pageaux G, Gerolami R, Habersetzer F, Nguyen-Khac E, Casadei-Gardini A, Borbath I, Tran A, Wege H, Saad AS, Colombo M, Abergel A, Richou C, Waked I, Yee NS, Molé A, Attali P, Le Boulicaut J, Vasseur B; RELIVE Investigators.

Lancet Gastroenterol Hepatol. 2019 Jun;4(6):454-465. doi: 10.1016/S2468-1253(19)30040-8. Epub 2019 Apr 4. Erratum in: Lancet Gastroenterol Hepatol. 2019 Jul;4(7):e6.

PMID:
30954567
4.

Special Issue: Cancer Biomarkers and Targets in Digestive Organs.

Yee NS, Lee NP.

Biomedicines. 2019 Jan 2;7(1). pii: E3. doi: 10.3390/biomedicines7010003.

5.

Frontiers in Gastrointestinal Oncology: Advances in Multi-Disciplinary Patient Care.

Yee NS, Lengerich EJ, Schmitz KH, Maranki JL, Gusani NJ, Tchelebi L, Mackley HB, Krok KL, Baker MJ, Boer C, Yee JD.

Biomedicines. 2018 Jun 1;6(2). pii: E64. doi: 10.3390/biomedicines6020064.

6.

Tumor Molecular Profiling for an Individualized Approach to the Treatment of Hepatocellular Carcinoma: A Patient Case Study.

Posadas K, Ankola A, Yang Z, Yee NS.

Biomedicines. 2018 Apr 17;6(2). pii: E46. doi: 10.3390/biomedicines6020046.

7.

Update in Systemic and Targeted Therapies in Gastrointestinal Oncology.

Yee NS.

Biomedicines. 2018 Mar 16;6(1). pii: E34. doi: 10.3390/biomedicines6010034.

8.

Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets.

Kankeu Fonkoua L, Yee NS.

Biomedicines. 2018 Mar 9;6(1). pii: E32. doi: 10.3390/biomedicines6010032. Review.

9.

The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma.

Coulson R, Liew SH, Connelly AA, Yee NS, Deb S, Kumar B, Vargas AC, O'Toole SA, Parslow AC, Poh A, Putoczki T, Morrow RJ, Alorro M, Lazarus KA, Yeap EFW, Walton KL, Harrison CA, Hannan NJ, George AJ, Clyne CD, Ernst M, Allen AM, Chand AL.

Oncotarget. 2017 Mar 21;8(12):18640-18656. doi: 10.18632/oncotarget.15553.

10.

Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary.

Balaban EP, Mangu PB, Yee NS.

J Oncol Pract. 2017 Apr;13(4):265-269. doi: 10.1200/JOP.2016.017376. Epub 2016 Oct 31. No abstract available.

PMID:
28399382
11.

Role of TRPM7 in Cancer: Potential as Molecular Biomarker and Therapeutic Target.

Yee NS.

Pharmaceuticals (Basel). 2017 Apr 5;10(2). pii: E39. doi: 10.3390/ph10020039. Review.

12.

Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB 3rd, Urba S, Yee NS.

J Clin Oncol. 2016 Aug 1;34(22):2654-68. doi: 10.1200/JCO.2016.67.5561. Epub 2016 May 31.

PMID:
27247216
13.

TRPM8 Ion Channels as Potential Cancer Biomarker and Target in Pancreatic Cancer.

Yee NS.

Adv Protein Chem Struct Biol. 2016;104:127-155. doi: 10.1016/bs.apcsb.2016.01.001. Epub 2016 Feb 22. Review.

PMID:
27038374
14.

Molecular genetics and targeted therapeutics in biliary tract carcinoma.

Marks EI, Yee NS.

World J Gastroenterol. 2016 Jan 28;22(4):1335-47. doi: 10.3748/wjg.v22.i4.1335. Review.

15.

ANIMAL MODELS OF CANCER BIOLOGY.

Yee NS, Ignatenko N, Finnberg N, Lee N, Stairs D.

Cancer Growth Metastasis. 2015 Dec 10;8(Suppl 1):115-8. doi: 10.4137/CGM.S37907. eCollection 2015. No abstract available.

16.

Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.

Ang C, Miura JT, Gamblin TC, He R, Xiu J, Millis SZ, Gatalica Z, Reddy SK, Yee NS, Abou-Alfa GK.

J Surg Oncol. 2016 Jan;113(1):55-61. doi: 10.1002/jso.24086. Epub 2015 Dec 10.

PMID:
26661118
17.

Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies.

Marks EI, Yee NS.

World J Gastrointest Oncol. 2015 Nov 15;7(11):338-46. doi: 10.4251/wjgo.v7.i11.338. Review.

18.

Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.

El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S.

Cancer Biol Ther. 2015;16(12):1726-37. doi: 10.1080/15384047.2015.1113356.

19.

Current Systemic Treatment and Emerging Therapeutic Strategies in Pancreatic Adenocarcinoma.

Yee NS, Kazi AA, Yee RK.

Curr Clin Pharmacol. 2015;10(4):256-66. Review.

PMID:
26548903
20.

EDITORIAL: Advances in Pharmacological Treatment of Cancer in Digestive Organs.

Yee NS.

Curr Clin Pharmacol. 2015;10(4):254-5. No abstract available.

PMID:
26548902
21.

Roles of TRPM8 Ion Channels in Cancer: Proliferation, Survival, and Invasion.

Yee NS.

Cancers (Basel). 2015 Oct 23;7(4):2134-46. doi: 10.3390/cancers7040882. Review.

22.

Molecular Genetics and Targeted Therapy in Hepatocellular Carcinoma.

Marks EI, Yee NS.

Curr Cancer Drug Targets. 2016;16(1):53-70.

PMID:
26373716
23.
24.

Aberrant over-expression of TRPM7 ion channels in pancreatic cancer: required for cancer cell invasion and implicated in tumor growth and metastasis.

Yee NS, Kazi AA, Li Q, Yang Z, Berg A, Yee RK.

Biol Open. 2015 Mar 13;4(4):507-14. doi: 10.1242/bio.20137088.

25.

Resolvins AT-D1 and E1 differentially impact functional outcome, post-traumatic sleep, and microglial activation following diffuse brain injury in the mouse.

Harrison JL, Rowe RK, Ellis TW, Yee NS, O'Hara BF, Adelson PD, Lifshitz J.

Brain Behav Immun. 2015 Jul;47:131-40. doi: 10.1016/j.bbi.2015.01.001. Epub 2015 Jan 10.

26.

Cellular and Developmental Biology of TRPM7 Channel-Kinase: Implicated Roles in Cancer.

Yee NS, Kazi AA, Yee RK.

Cells. 2014 Jul 30;3(3):751-77. doi: 10.3390/cells3030751.

27.

Aberrantly Over-Expressed TRPM8 Channels in Pancreatic Adenocarcinoma: Correlation with Tumor Size/Stage and Requirement for Cancer Cells Invasion.

Yee NS, Li Q, Kazi AA, Yang Z, Berg A, Yee RK.

Cells. 2014 May 23;3(2):500-16. doi: 10.3390/cells3020500.

28.

Knowledge of medication use and factors influencing the utilisation of public health clinics.

Naing C, Kai YC, Yi CH, Yee NS, Yi LM, Jun LX, Kin WC, Selvanathan SA.

Int Health. 2013 Sep;5(3):217-22.

PMID:
24159624
29.

Translating discovery in zebrafish pancreatic development to human pancreatic cancer: biomarkers, targets, pathogenesis, and therapeutics.

Yee NS, Kazi AA, Yee RK.

Zebrafish. 2013 Jun;10(2):132-46. doi: 10.1089/zeb.2012.0817. Epub 2013 May 17.

30.

Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial.

Welsh JL, Wagner BA, van't Erve TJ, Zehr PS, Berg DJ, Halfdanarson TR, Yee NS, Bodeker KL, Du J, Roberts LJ 2nd, Drisko J, Levine M, Buettner GR, Cullen JJ.

Cancer Chemother Pharmacol. 2013 Mar;71(3):765-75. doi: 10.1007/s00280-013-2070-8. Epub 2013 Feb 5.

31.

Toward the goal of personalized therapy in pancreatic cancer by targeting the molecular phenotype.

Yee NS.

Adv Exp Med Biol. 2013;779:91-143. doi: 10.1007/978-1-4614-6176-0_5. Review.

PMID:
23288637
32.

Targeting developmental regulators of zebrafish exocrine pancreas as a therapeutic approach in human pancreatic cancer.

Yee NS, Zhou W, Chun SG, Liang IC, Yee RK.

Biol Open. 2012 Apr 15;1(4):295-307. doi: 10.1242/bio.2012539. Epub 2012 Feb 10.

33.

Microwave-assisted synthesis of sec/tert-butyl 2-arylbenzimidazoles and their unexpected antiproliferative activity towards ER negative breast cancer cells.

Abdul Rahim AS, Salhimi SM, Arumugam N, Pin LC, Yee NS, Muttiah NN, Keat WB, Abd Hamid S, Osman H, Mat Ib.

J Enzyme Inhib Med Chem. 2013 Dec;28(6):1255-60. doi: 10.3109/14756366.2012.729828. Epub 2012 Oct 15.

PMID:
23061895
34.

TRPM8 ion channel is aberrantly expressed and required for preventing replicative senescence in pancreatic adenocarcinoma: potential role of TRPM8 as a biomarker and target.

Yee NS, Brown RD, Lee MS, Zhou W, Jensen C, Gerke H, Yee RK.

Cancer Biol Ther. 2012 Jun;13(8):592-9. doi: 10.4161/cbt.20079. Epub 2012 Jun 1.

35.

TRPM7 and TRPM8 Ion Channels in Pancreatic Adenocarcinoma: Potential Roles as Cancer Biomarkers and Targets.

Yee NS, Chan AS, Yee JD, Yee RK.

Scientifica (Cairo). 2012;2012:415158. doi: 10.6064/2012/415158. Epub 2012 Jul 19. Review.

36.

Targeted silencing of TRPM7 ion channel induces replicative senescence and produces enhanced cytotoxicity with gemcitabine in pancreatic adenocarcinoma.

Yee NS, Zhou W, Lee M, Yee RK.

Cancer Lett. 2012 May 1;318(1):99-105. doi: 10.1016/j.canlet.2011.12.007. Epub 2011 Dec 11.

37.

Brca2 deficiency and Trp53 deregulation in pancreatic cancer: implications for therapeutic targeting.

Yee NS.

Cancer Biol Ther. 2011 Jun 1;11(11):969-73. Epub 2011 Jun 1. No abstract available.

PMID:
21610317
38.

Pancreatic Adenocarcinoma Associated With Werner's Syndrome (Adult-Onset Progeria).

Chun SG, Yee NS, Holland JM, Shohet RV, Palalay MP, Bryant-Greenwood PK.

Gastrointest Cancer Res. 2011 Jan;4(1):24-8. No abstract available.

39.

Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development and cancer.

Zhou W, Liang IC, Yee NS.

Cancer Biol Ther. 2011 Apr 1;11(7):659-70. Epub 2011 Apr 1.

40.
41.
42.

Transient receptor potential channel TRPM8 is over-expressed and required for cellular proliferation in pancreatic adenocarcinoma.

Yee NS, Zhou W, Lee M.

Cancer Lett. 2010 Nov 1;297(1):49-55. doi: 10.1016/j.canlet.2010.04.023. Epub 2010 Jun 1.

43.

Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer.

Chun SG, Zhou W, Yee NS.

Cancer Biol Ther. 2009 Jul;8(14):1328-39. Epub 2009 Jul 6.

PMID:
19421011
44.

Mutation of RNA Pol III subunit rpc2/polr3b Leads to Deficiency of Subunit Rpc11 and disrupts zebrafish digestive development.

Yee NS, Gong W, Huang Y, Lorent K, Dolan AC, Maraia RJ, Pack M.

PLoS Biol. 2007 Nov;5(11):e312.

45.

Clinical remission of acquired thrombasthenia with low-dose methotrexate in a patient with systemic lupus erythematosus.

Yee NS, Schuster SJ.

Mayo Clin Proc. 2006 Apr;81(4):566-7. No abstract available.

PMID:
16610580
46.

Exocrine pancreas development in zebrafish.

Yee NS, Lorent K, Pack M.

Dev Biol. 2005 Aug 1;284(1):84-101.

47.

Differential requirement for ptf1a in endocrine and exocrine lineages of developing zebrafish pancreas.

Lin JW, Biankin AV, Horb ME, Ghosh B, Prasad NB, Yee NS, Pack MA, Leach SD.

Dev Biol. 2004 Oct 15;274(2):491-503.

48.

Zebrafish as a model for pancreatic cancer research.

Yee NS, Pack M.

Methods Mol Med. 2005;103:273-98.

PMID:
15542913
49.

Differential requirement for ptf1a in endocrine and exocrine lineages of developing zebrafish pancreas.

Lin JW, Biankin AV, Horb ME, Ghosh B, Prasad NB, Yee NS, Pack MA, Leach SD.

Dev Biol. 2004 Jun 15;270(2):474-86. Erratum in: Dev Biol. 2004 Oct 15;274(2):490.

50.

Clinicopathologic and molecular features of pancreatic adenocarcinoma associated with Peutz-Jeghers syndrome.

Yee NS, Furth EE, Pack M.

Cancer Biol Ther. 2003 Jan-Feb;2(1):38-47. Review.

PMID:
12673116

Supplemental Content

Support Center